Monarch Partners Asset Management LLC boosted its position in ANI Pharmaceuticals Inc (NASDAQ:ANIP) by 13.4% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 4,910 shares of the specialty pharmaceutical company’s stock after purchasing an additional 580 shares during the quarter. Monarch Partners Asset Management LLC’s holdings in ANI Pharmaceuticals were worth $358,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. BlackRock Inc. lifted its stake in ANI Pharmaceuticals by 5.1% in the 2nd quarter. BlackRock Inc. now owns 1,429,732 shares of the specialty pharmaceutical company’s stock worth $117,524,000 after purchasing an additional 69,621 shares in the last quarter. Vanguard Group Inc. lifted its stake in ANI Pharmaceuticals by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 564,317 shares of the specialty pharmaceutical company’s stock worth $46,387,000 after purchasing an additional 12,859 shares in the last quarter. Nomura Holdings Inc. lifted its stake in ANI Pharmaceuticals by 34.1% in the 2nd quarter. Nomura Holdings Inc. now owns 375,449 shares of the specialty pharmaceutical company’s stock worth $31,071,000 after purchasing an additional 95,462 shares in the last quarter. First Manhattan Co. lifted its stake in ANI Pharmaceuticals by 22.8% in the 2nd quarter. First Manhattan Co. now owns 294,852 shares of the specialty pharmaceutical company’s stock worth $24,236,000 after purchasing an additional 54,686 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in ANI Pharmaceuticals by 44.6% in the 2nd quarter. Renaissance Technologies LLC now owns 288,100 shares of the specialty pharmaceutical company’s stock worth $23,682,000 after purchasing an additional 88,900 shares in the last quarter. Institutional investors and hedge funds own 70.97% of the company’s stock.
In other news, major shareholder Meridian Venture Partners Ii L sold 7,579 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $68.21, for a total value of $516,963.59. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders sold 78,591 shares of company stock valued at $5,582,839. Corporate insiders own 24.70% of the company’s stock.
Shares of NASDAQ:ANIP traded down $4.05 during trading on Friday, reaching $57.38. The company had a trading volume of 388,900 shares, compared to its average volume of 137,916. The stock has a market capitalization of $954.49 million, a P/E ratio of 12.45 and a beta of 2.20. ANI Pharmaceuticals Inc has a 12 month low of $36.92 and a 12 month high of $86.96. The company has a current ratio of 1.01, a quick ratio of 0.74 and a debt-to-equity ratio of 0.32. The company has a fifty day moving average of $73.65 and a two-hundred day moving average of $73.58.
ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Wednesday, November 6th. The specialty pharmaceutical company reported $1.23 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.43 by ($0.20). ANI Pharmaceuticals had a return on equity of 29.53% and a net margin of 8.14%. The company had revenue of $51.30 million during the quarter, compared to analysts’ expectations of $56.10 million. During the same period in the prior year, the business posted $1.29 earnings per share. The company’s revenue for the quarter was up 1.2% on a year-over-year basis. As a group, equities research analysts predict that ANI Pharmaceuticals Inc will post 5.29 earnings per share for the current year.
A number of equities analysts have recently commented on the stock. Raymond James decreased their price target on shares of ANI Pharmaceuticals from $82.00 to $75.00 and set an “outperform” rating on the stock in a report on Thursday. ValuEngine lowered shares of ANI Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday. Guggenheim assumed coverage on shares of ANI Pharmaceuticals in a report on Thursday, September 12th. They issued a “buy” rating and a $76.00 price target on the stock. Zacks Investment Research raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, October 4th. Finally, BidaskClub raised shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, October 22nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. ANI Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $85.00.
ANI Pharmaceuticals Profile
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.
Featured Article: After-Hours Trading
Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals Inc (NASDAQ:ANIP).
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.